Zydus Lifesciences (BOM:532321) EV-to-Revenue : 5.30 (As of May. 14, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Zydus Lifesciences's enterprise value is ₹981,136 Mil. Zydus Lifesciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₹185,076 Mil. Therefore, Zydus Lifesciences's EV-to-Revenue for today is 5.30.

The historical rank and industry rank for Zydus Lifesciences's EV-to-Revenue or its related term are showing as below:

BOM:532321' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.67 Med: 3.41 Max: 6.29
Current: 5.31

During the past 13 years, the highest EV-to-Revenue of Zydus Lifesciences was 6.29. The lowest was 1.67. And the median was 3.41.

BOM:532321's EV-to-Revenue is ranked worse than
77.58% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.375 vs BOM:532321: 5.31

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-14), Zydus Lifesciences's stock price is ₹993.20. Zydus Lifesciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₹182.87. Therefore, Zydus Lifesciences's PS Ratio for today is 5.43.

Zydus Lifesciences EV-to-Revenue Historical Data

The historical data trend for Zydus Lifesciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences EV-to-Revenue Chart

Zydus Lifesciences Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-Revenue

Get a 7-Day Free Trial

3.43

2.57

3.58

2.60

3.08

Zydus Lifesciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															2.70	3.08	3.28	3.42	3.77

Competitive Comparison of Zydus Lifesciences's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zydus Lifesciences's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's EV-to-Revenue falls into.

Zydus Lifesciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Zydus Lifesciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	981135.599	/	185076
	=	5.30

Zydus Lifesciences's current Enterprise Value is ₹981,136 Mil.
Zydus Lifesciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹185,076 Mil.

Zydus Lifesciences (BOM:532321) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Zydus Lifesciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	993.20	/	182.866
	=	5.43

Zydus Lifesciences's share price for today is ₹993.20.
Zydus Lifesciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹182.87.

Zydus Lifesciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Zydus Lifesciences (BOM:532321) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » EV-to-Revenue

Traded in Other Exchanges

ZYDUSLIFE:India

Address

Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481

Website

https://www.zyduslife.com

Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines